Grauer & Weil (India) Ltd
GRAUWEILGrauer & Weil (India) Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is in a downtrend (3 weeks in) while the P/E sits at the 59th percentile of its own 11-year range. Underneath, the last four quarters read deteriorating — profit −9.1% year on year, and 98% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Grauer & Weil (India) Ltd trades at ₹75.5, in a downtrend and 3 weeks into that stage. That is +2.1% against its own 200-day average. It sits at 72% of a 52-week range of ₹55 to ₹83. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week.
Today the stock is in a downtrend — week 3 of stage 4, confirmed. At ₹75.5 it trades +2.1% versus its 200-day average and sits at 72% of its 52-week range (₹55–₹83).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +541% while the NIFTY 500 moved +267% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Grauer & Weil (India) Ltd trades at 21.4× P/E, mid-range by its own standards (59th percentile). Its long-run median P/E is 20.2×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 21.4× is mid-range by its own standards (59th percentile), against a long-run median of 20.2× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +4.3% against a −18.8% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +20.5%/yr price move, ~+13.1%/yr came from earnings growth and ~+7.4 pp from the multiple (expanding); over 10y, of the +16.3%/yr price move, ~+13.9%/yr came from earnings growth and ~+2.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, Grauer & Weil (India) Ltd was paying for profit growth of about 10.5% a year. Profit itself has compounded 14.6% a year over the past 10 years. Today the market pays 21.4× P/E, the 59th percentile of its own 11-year range.
What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is close to what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Grauer & Weil (India) Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 20.5% and holding. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +5.0% | +6.6% | +14.5% | +11.2% |
| Profit | +4.5% | +13.2% | +18.9% | +14.6% |
| EPS | +4.3% | +13.3% | +19.0% | +14.6% |
| Share price | −18.8% | +2.9% | +20.5% | +16.3% |
4-Factor Sector Score
41.5/100 — rank 21 of 28 in Speciality Chemicals · 100% evidence confidence
Grauer & Weil (India) Ltd scores 41.5 out of 100 against the 28 companies it is compared with in Speciality Chemicals, ranking 21. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 10.4 + 16.1 + 8.2 + 6.8 = 41.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Grauer & Weil (India) Ltd reported ₹299 Cr of revenue in the Jun 26 quarter, +18.2% year on year. That is the 4th straight quarter of year-on-year growth. Over 10 years it has compounded at 11.2% a year. The last full year, FY26, came in at ₹1,190 Cr. The last four reported quarters add to ₹1,236 Cr.
FY26 revenue came in at ₹1,190 Cr (+5.0% on the year), capping 10 years at 11.2% compound. The latest quarter (Jun 26) printed ₹299 Cr, +18.2% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +10.6% growth against the decade's 11.2% — the current year is running in line with its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +10.1% over the last 4 quarters against +4.5%/yr over the last 8 — accelerating; TTM profit +6.6% vs +0.3%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Grauer & Weil (India) Ltd's operating margin is 16.0% in the Jun 26 quarter, −5.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 15.0% to 20.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 16.0%, −5.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 15.0%–20.0%.
🚨 Why the margin moved: operating margin went −4.6 pp year on year while gross margin went −8.6 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Grauer & Weil (India) Ltd earned ₹40.0 Cr of net profit in the Jun 26 quarter, −9.1% year on year. Full-year FY26 profit was ₹164 Cr. The 10-year compound rate is 14.6%. That is 13.4% of the quarter's revenue. The same quarter a year earlier earned ₹44.0 Cr.
Jun 26 profit was ₹40.0 Cr, −9.1% year on year. On the full year, FY26 printed ₹164 Cr (+4.5%), and the 10-year compound rate is 14.6%.
🚨 Why profit moved: revenue contributed +18.2% and the margin −5.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +15.0% vs revenue +10.6%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 98% of Grauer & Weil (India) Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹152 Cr of operating cash against ₹164 Cr of profit. After ₹57.0 Cr of capital spending, ₹95.0 Cr was left as free cash.
FY26: operating cash of ₹152 Cr against reported profit of ₹164 Cr, leaving free cash of ₹95.0 Cr after ₹57.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 98% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 98%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 2.0× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Grauer & Weil (India) Ltd's cash conversion cycle runs 67 days in FY26, down from 75 days in FY21. Capital spending ran ₹134 Cr over the last 3 years. At FY26 sales of ₹1,190 Cr each day of that cycle holds about ₹3.3 Cr, so roughly ₹218 Cr sits inside the business at any moment.
FY26: debtors at 54 days, inventory at 112 days — roughly 3.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 67 days, tighter than FY21's 75.
The full loop: cash goes out to suppliers and production on day 0; stock waits 112 days to sell; customers pay about 54 days after that; and suppliers themselves are paid at 99 days — netting out to the 67-day cycle.
In money terms: at FY26 sales of ₹1,190 Cr, each day of the cycle holds about ₹3.3 Cr — so the 67-day loop keeps roughly ₹218 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹134 Cr over the last 3 fiscal years against ₹67.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹37.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Grauer & Weil (India) Ltd earns a ROCE of 21% in FY26. That is up from a trough of 18% in FY14. Return on invested capital clears the cost of that capital by +7.5 percentage points, so growth here adds value rather than only size. The wiring behind it is 13.8% net margin on 0.82× asset turns.
FY26 ROCE is 21%, recovered from a FY14 trough of 18% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 13.8% net margin × 0.82× asset turns × 1.34× balance-sheet leverage ≈ 15.2% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 19.5% − 12.0% = a +7.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Grauer & Weil (India) Ltd carries total debt of ₹15.0 Cr against shareholder equity of ₹1,082 Cr as of Mar 26, a debt-to-equity of 0.01 — effectively unlevered. On the annual view that ratio went from 0.04 in FY22 to 0.01 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹15.0 Cr against shareholder equity of ₹1,082 Cr — a debt-to-equity of 0.01. On the annual view, debt-to-equity went from 0.04 (FY22) to 0.01 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Grauer & Weil (India) Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved +0.0 points over the same window, to 69.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −0.6 points over 8 quarters to 0.3%; Promoters: +0.0 points over 8 quarters to 69.0%; Domestic institutions: +0.0 points over 8 quarters to 0.1%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Grauer & Weil (India) Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Panama Petrochem LtdPANAMAPET | 74.9/100Favorable setup100% evidence | LEADER | 28.1/35 Revenue 45.9% · PAT 100% · OPM change 14 pp 100% evidence | 14.9/25 ROCE 19.2% · OPM 22% 100% evidence | 15.4/20 P/E 6.1× · PEG 0.55 100% evidence | 16.5/20 RS sector 18.7% · RS bench 46.9% · 1Y 64.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 28.1 + 14.9 + 15.4 + 16.5 = 74.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Sunshield Chemicals Ltd530845 | 69.8/100Favorable setup76% evidence | FADING | 28.0/35 Revenue 12.9% · PAT 100% · OPM change 5 pp 95% evidence | 16.6/25 ROCE 19.9% · OPM 16% 76% evidence | 11.3/20 P/E 29.1× · PEG — 50% evidence | 13.9/20 RS sector 2.3% · RS bench 24.5% · 1Y 16.2%10 of 11 weeks ahead 70% evidence |
| Exact sum: 28 + 16.6 + 11.3 + 13.9 = 69.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Vikram Thermo (India) Ltd530477 | 65.5/100Favorable setup67% evidence | BREAKING OUT | 25.5/35 Revenue 16.9% · PAT 41.9% · OPM change 8 pp 95% evidence | 19.8/25 ROCE 36.2% · OPM 48% 76% evidence | 7.9/20 P/E 24.3× · PEG — 50% evidence | 12.3/20 RS sector — · RS bench 83.6% · 1Y —10 of 10 weeks ahead 25% evidence |
| Exact sum: 25.5 + 19.8 + 7.9 + 12.3 = 65.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 4Black Rose Industries LtdBLACKROSE | 64.2/100Mixed-positive evidence72% evidence | BREAKING OUT | 22.0/35 Revenue 8.6% · PAT 28.6% · OPM change 6 pp 95% evidence | 17.1/25 ROCE 18.7% · OPM 16% 95% evidence | 14.5/20 P/E 19.2× · PEG — 50% evidence | 10.6/20 RS sector — · RS bench 11.6% · 1Y —4 of 6 weeks ahead 25% evidence |
| Exact sum: 22 + 17.1 + 14.5 + 10.6 = 64.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Yasho Industries LtdYASHO | 62.9/100Mixed-positive evidence87% evidence | BREAKING OUT | 29.3/35 Revenue 34.1% · PAT 100% · OPM change 7 pp 100% evidence | 8.6/25 ROCE 8.9% · OPM 24% 100% evidence | 12.0/20 P/E 87.6× · PEG 1.15 65% evidence | 13.0/20 RS sector -2.4% · RS bench 102% · 1Y 131.1%11 of 11 weeks ahead 70% evidence |
| Exact sum: 29.3 + 8.6 + 12 + 13 = 62.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Privi Speciality Chemicals LtdPRIVISCL | 59.9/100Mixed-positive evidence75% evidence | FADING | 25.0/35 Revenue 21.6% · PAT 62.1% · OPM change -1 pp 95% evidence | 17.9/25 ROCE 22.3% · OPM 23% 76% evidence | 9.5/20 P/E 39.7× · PEG — 15% evidence | 7.5/20 RS sector -8.1% · RS bench 15.3% · 1Y 55.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 25 + 17.9 + 9.5 + 7.5 = 59.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Aether Industries LtdAETHER | 58.4/100Mixed-positive evidence100% evidence | BREAKING OUT | 24.4/35 Revenue 34.4% · PAT 34.3% · OPM change -1 pp 100% evidence | 10.7/25 ROCE 11.9% · OPM 31% 100% evidence | 4.2/20 P/E 92.6× · PEG 8.9 100% evidence | 19.1/20 RS sector 23.6% · RS bench 53.6% · 1Y 125.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 10.7 + 4.2 + 19.1 = 58.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8DMCC Speciality Chemicals LtdDMCC | 56.8/100Mixed-positive evidence80% evidence | TURNING | 24.4/35 Revenue 49.7% · PAT 42.9% · OPM change 0 pp 95% evidence | 11.0/25 ROCE 14.8% · OPM 13% 95% evidence | 11.4/20 P/E 17.9× · PEG — 15% evidence | 10.0/20 RS sector -12.3% · RS bench 10% · 1Y -6.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 11 + 11.4 + 10 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Pidilite Industries LtdPIDILITIND | 56.7/100Mixed-positive evidence100% evidence | FADING | 22.6/35 Revenue 14.1% · PAT 21.5% · OPM change 1 pp 100% evidence | 20.6/25 ROCE 31% · OPM 26% 100% evidence | 7.9/20 P/E 60.2× · PEG 3.8 100% evidence | 5.6/20 RS sector -15.4% · RS bench 6.4% · 1Y 1.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 22.6 + 20.6 + 7.9 + 5.6 = 56.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Tatva Chintan Pharma Chem LtdTATVA | 56.0/100Mixed-positive evidence93% evidence | BREAKING OUT | 30.4/35 Revenue 41.1% · PAT 100% · OPM change 4 pp 100% evidence | 6.5/25 ROCE 7.2% · OPM 19% 100% evidence | 4.7/20 P/E 71.8× · PEG 5.63 65% evidence | 14.4/20 RS sector -1.5% · RS bench 23.3% · 1Y 61.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 30.4 + 6.5 + 4.7 + 14.4 = 56 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Fineotex Chemical LtdFCL | 54.0/100Mixed-positive evidence100% evidence | LEADER | 18.4/35 Revenue 91.5% · PAT 41% · OPM change -2 pp 100% evidence | 12.7/25 ROCE 18.3% · OPM 16% 100% evidence | 3.0/20 P/E 54.9× · PEG 4.19 100% evidence | 19.9/20 RS sector 58% · RS bench 94.1% · 1Y 143.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 12.7 + 3 + 19.9 = 54 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Aarti Industries LtdAARTIIND | 53.5/100Mixed-positive evidence100% evidence | BREAKING OUT | 27.7/35 Revenue 27% · PAT 100% · OPM change 3 pp 100% evidence | 8.3/25 ROCE 6.9% · OPM 16% 100% evidence | 9.0/20 P/E 34.2× · PEG 2.05 100% evidence | 8.5/20 RS sector -8.2% · RS bench 15.1% · 1Y 30.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 27.7 + 8.3 + 9 + 8.5 = 53.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Kronox Lab Sciences LtdKRONOX | 53.3/100Mixed-positive evidence65% evidence | BREAKING OUT | 9.4/35 Revenue 6.1% · PAT 11.6% · OPM change -1.1 pp 95% evidence | 21.6/25 ROCE 36% · OPM 31.7% 95% evidence | 10.8/20 P/E 22.8× · PEG — 15% evidence | 11.5/20 RS sector — · RS bench 24.8% · 1Y —5 of 5 weeks ahead 25% evidence |
| Exact sum: 9.4 + 21.6 + 10.8 + 11.5 = 53.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Chemcon Speciality Chemicals LtdCHEMCON | 51.1/100Mixed-positive evidence81% evidence | TURNING | 21.0/35 Revenue 16.7% · PAT 12% · OPM change 8 pp 95% evidence | 10.7/25 ROCE 6.3% · OPM 23% 95% evidence | 12.1/20 P/E 28.2× · PEG — 50% evidence | 7.3/20 RS sector -21.7% · RS bench 13.7% · 1Y 4.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 10.7 + 12.1 + 7.3 = 51.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Vishnu Chemicals LtdVISHNU | 47.7/100Mixed-negative evidence100% evidence | BREAKING OUT | 15.5/35 Revenue 16.5% · PAT 17.2% · OPM change -1 pp 100% evidence | 11.3/25 ROCE 16.4% · OPM 15% 100% evidence | 5.6/20 P/E 32.1× · PEG 2.82 100% evidence | 15.3/20 RS sector 4.7% · RS bench 31.2% · 1Y 48.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 11.3 + 5.6 + 15.3 = 47.7 · Decision use: Price leads the evidence: RS versus the benchmark is 31.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16Galaxy Surfactants LtdGALAXYSURF | 47.3/100Mixed-negative evidence94% evidence | BREAKING OUT | 19.5/35 Revenue 27% · PAT 15.7% · OPM change 4 pp 100% evidence | 9.4/25 ROCE 13.5% · OPM 14% 100% evidence | 9.6/20 P/E 21.3× · PEG 4.39 100% evidence | 8.8/20 RS sector -12.1% · RS bench 11.3% · 1Y -6.7%8 of 10 weeks ahead 70% evidence |
| Exact sum: 19.5 + 9.4 + 9.6 + 8.8 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Alkyl Amines Chemicals LtdALKYLAMINE | 46.8/100Mixed-negative evidence100% evidence | FADING | 18.4/35 Revenue 5.1% · PAT 21% · OPM change 6 pp 100% evidence | 15.6/25 ROCE 16.6% · OPM 25% 100% evidence | 5.6/20 P/E 42.4× · PEG 5.37 100% evidence | 7.2/20 RS sector -10.8% · RS bench 11.6% · 1Y -9.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 15.6 + 5.6 + 7.2 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Vinati Organics LtdVINATIORGA | 44.4/100Mixed-negative evidence82% evidence | TURNING | 11.2/35 Revenue 5.1% · PAT 5.7% · OPM change -5 pp 95% evidence | 17.5/25 ROCE 19.8% · OPM 24% 76% evidence | 13.4/20 P/E 29.9× · PEG — 50% evidence | 2.3/20 RS sector -28.7% · RS bench -9.8% · 1Y -23.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 17.5 + 13.4 + 2.3 = 44.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19Amal LtdAMAL | 43.0/100Mixed-negative evidence69% evidence | 8.0/35 Revenue 79% · PAT -23.1% · OPM change -7 pp 95% evidence | 16.4/25 ROCE 26% · OPM 18% 76% evidence | 10.0/20 P/E 30.7× · PEG — 15% evidence | 8.6/20 RS sector -18.2% · RS bench 15.4% · 1Y -20%0 of 12 weeks ahead 70% evidence | |
| Exact sum: 8 + 16.4 + 10 + 8.6 = 43 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Platinum Industries LtdPLATIND | 42.5/100Mixed-negative evidence74% evidence | BASING | 12.8/35 Revenue 9.6% · PAT 6.5% · OPM change -1 pp 95% evidence | 12.3/25 ROCE 15.7% · OPM 12% 95% evidence | 10.6/20 P/E 23.9× · PEG — 15% evidence | 6.8/20 RS sector -10.6% · RS bench -6.1% · 1Y -22.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.8 + 12.3 + 10.6 + 6.8 = 42.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Grauer & Weil (India) Ltdthis pageGRAUWEIL | 41.5/100Mixed-negative evidence100% evidence | TURNING | 10.4/35 Revenue 10.1% · PAT 6.6% · OPM change -5 pp 100% evidence | 16.1/25 ROCE 20.6% · OPM 16% 100% evidence | 8.2/20 P/E 21.4× · PEG 4.01 100% evidence | 6.8/20 RS sector -17.8% · RS bench 3.4% · 1Y -18.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 10.4 + 16.1 + 8.2 + 6.8 = 41.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Anupam Rasayan India LtdANURAS | 41.5/100Mixed-negative evidence82% evidence | ASLEEP | 20.0/35 Revenue 51.7% · PAT 14.8% · OPM change -1 pp 95% evidence | 10.5/25 ROCE 7.4% · OPM 25% 76% evidence | 8.3/20 P/E 79.5× · PEG — 50% evidence | 2.7/20 RS sector -21.7% · RS bench -1% · 1Y 9.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 10.5 + 8.3 + 2.7 = 41.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Neogen Chemicals LtdNEOGEN | 40.5/100Mixed-negative evidence90% evidence | LEADER | 14.7/35 Revenue 18.1% · PAT 6.1% · OPM change 2 pp 100% evidence | 6.7/25 ROCE 6.5% · OPM 19% 100% evidence | 5.2/20 P/E 183× · PEG — 50% evidence | 13.9/20 RS sector 22.9% · RS bench 52% · 1Y 59.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 14.7 + 6.7 + 5.2 + 13.9 = 40.5 · Decision use: Price leads the evidence: RS versus the benchmark is 52%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 24Paushak LtdPAUSHAKLTD | 37.0/100Mixed-negative evidence81% evidence | BREAKING OUT | 11.9/35 Revenue 15.4% · PAT -15.7% · OPM change -1 pp 95% evidence | 10.0/25 ROCE 8.3% · OPM 31% 95% evidence | 7.5/20 P/E 42.4× · PEG — 50% evidence | 7.6/20 RS sector -27.5% · RS bench 28% · 1Y -4.6%11 of 11 weeks ahead 70% evidence |
| Exact sum: 11.9 + 10 + 7.5 + 7.6 = 37 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Clean Science & Technology LtdCLEAN | 36.3/100Mixed-negative evidence94% evidence | BREAKING OUT | 4.5/35 Revenue -0.4% · PAT -13.8% · OPM change -5 pp 100% evidence | 18.5/25 ROCE 20.7% · OPM 36% 100% evidence | 7.8/20 P/E 38.4× · PEG 6.24 100% evidence | 5.5/20 RS sector -24.4% · RS bench 1.4% · 1Y -29.2%2 of 10 weeks ahead 70% evidence |
| Exact sum: 4.5 + 18.5 + 7.8 + 5.5 = 36.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Amines & Plasticizers LtdAMNPLST | 35.5/100Mixed-negative evidence81% evidence | ASLEEP | 7.8/35 Revenue -12.4% · PAT -3% · OPM change 0.7 pp 95% evidence | 14.0/25 ROCE 16.7% · OPM 9.9% 95% evidence | 8.8/20 P/E 23.6× · PEG — 50% evidence | 4.9/20 RS sector -19.4% · RS bench -9.2% · 1Y -27.6%5 of 10 weeks ahead 70% evidence |
| Exact sum: 7.8 + 14 + 8.8 + 4.9 = 35.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Transpek Industry LtdTRANSPEK | 34.5/100Adverse evidence81% evidence | TURNING | 6.4/35 Revenue -5.2% · PAT -29.1% · OPM change -2.3 pp 95% evidence | 9.1/25 ROCE 8.4% · OPM 13.3% 95% evidence | 11.3/20 P/E 19.3× · PEG — 50% evidence | 7.7/20 RS sector -19.7% · RS bench 11.7% · 1Y -4.7%4 of 10 weeks ahead 70% evidence |
| Exact sum: 6.4 + 9.1 + 11.3 + 7.7 = 34.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Thirumalai Chemicals LtdTIRUMALCHM | 25.9/100Adverse evidence69% evidence | BASING | 13.1/35 Revenue -5.8% · PAT -36.9% · OPM change 12 pp 71% evidence | 1.1/25 ROCE -3.1% · OPM 6% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 1.7/20 RS sector -39.8% · RS bench -23.6% · 1Y -49%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.1 + 1.1 + 10 + 1.7 = 25.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Grauer & Weil (India) Ltd's share price today?
Grauer & Weil (India) Ltd trades at ₹75.5, −18.8% over the past year. The company is valued at ₹3,428 Cr. The stock sits at 72% of its 52-week range of ₹55–₹83, +2.1% versus its 200-day average. On the tape, the price is in a downtrend, 3 weeks in. — as of 11 September 2026.
What were Grauer & Weil (India) Ltd's latest quarterly results?
Grauer & Weil (India) Ltd reported revenue of ₹299 Cr and net profit of ₹40.0 Cr for the Jun 26 quarter. Revenue rose 18.2% and profit fell 9.1% year on year. Earnings per share were ₹0.88. The operating margin was 16.0%, 5.0 pp lower than a year earlier. — as of 11 September 2026.
What is Grauer & Weil (India) Ltd's revenue?
Grauer & Weil (India) Ltd reported revenue of ₹299 Cr in the Jun 26 quarter, +18.2% year on year. For the full FY26 fiscal year, revenue was ₹1,190 Cr (+5.0%). Over the last 10 years revenue compounded at 11.2% a year. — as of 11 September 2026.
What is Grauer & Weil (India) Ltd's profit?
Grauer & Weil (India) Ltd earned ₹40.0 Cr of net profit in the Jun 26 quarter, −9.1% year on year. Full-year FY26 profit was ₹164 Cr. The operating margin ran 16.0% in the latest quarter. — as of 11 September 2026.
What is Grauer & Weil (India) Ltd's market cap?
Grauer & Weil (India) Ltd's market capitalisation is ₹3,428 Cr at a share price of ₹75.5. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Grauer & Weil (India) Ltd's P/E ratio?
Grauer & Weil (India) Ltd trades at a P/E of 21.4×, at the 59th percentile of its own 11-year range, against a long-run median of 20.2×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Grauer & Weil (India) Ltd pay a dividend?
Yes — Grauer & Weil (India) Ltd's dividend payout was 28% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Grauer & Weil (India) Ltd overvalued?
On its own history, Grauer & Weil (India) Ltd looks mid-range: its P/E of 21.4× sits at the 59th percentile of its 11-year range (long-run median 20.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Grauer & Weil (India) Ltd growing?
Not right now — Grauer & Weil (India) Ltd's latest numbers are shrinking: latest-quarter revenue +18.2% year on year, profit −9.1%, and the margin −5.0 pp at 16.0%. The 10-year compound rates are 11.2% (revenue) and 14.6% (profit). The earnings engine currently reads: deteriorating — as of 11 September 2026.
How is Grauer & Weil (India) Ltd performing?
Grauer & Weil (India) Ltd is in a downtrend, 3 weeks in. Its latest quarter's revenue rose 18.2% and profit fell 9.1% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Grauer & Weil (India) Ltd in?
Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 20.5% and holding. The read comes from the last 12 quarters of growth (revenue growth +10.1% latest, profit growth +6.6% latest, eps growth +6.6% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Grauer & Weil (India) Ltd in an uptrend?
No — the price is in a downtrend (week 3 of stage 4), trading +2.1% versus its 200-day average and at 72% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Grauer & Weil (India) Ltd beating the market?
On recent form, yes — Grauer & Weil (India) Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +541% against the NIFTY 500's +267% — ahead of the index over the full window. — as of 11 September 2026.
Will Grauer & Weil (India) Ltd's share price go up?
This page publishes no price forecast for Grauer & Weil (India) Ltd. What it measures instead: the share price is ₹75.5, the price is in a downtrend 3 weeks in. Its P/E of 21.4× sits at the 59th percentile of its own 11-year range. — as of 11 September 2026.
Who owns Grauer & Weil (India) Ltd?
Promoters hold 69.0% of Grauer & Weil (India) Ltd, foreign institutions 0.3%, domestic institutions 0.1% and the public 30.6% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does Grauer & Weil (India) Ltd have too much debt?
No — Grauer & Weil (India) Ltd's debt-to-equity is 0.01, and operating profit covers the interest bill 49×. FY26 borrowings were ₹15.0 Cr against equity of ₹1,081 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Grauer & Weil (India) Ltd's capex?
Grauer & Weil (India) Ltd spent ₹134 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹57.0 Cr, with ₹37.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Grauer & Weil (India) Ltd's cash flow?
Grauer & Weil (India) Ltd generated ₹152 Cr of operating cash flow in FY26 and ₹95.0 Cr of free cash flow after ₹57.0 Cr of capital spending. Reported profit that year was ₹164 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Grauer & Weil (India) Ltd's profit real cash?
Yes — over the last 3 fiscal years, 98% of Grauer & Weil (India) Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹152 Cr against reported profit of ₹164 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Grauer & Weil (India) Ltd in its business cycle?
Grauer & Weil (India) Ltd's FY26 operating margin was 16.0%, against a 13-year band of 15.0%–20.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 16.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Grauer & Weil (India) Ltd's price assume?
At its price on 13 June 2026, Grauer & Weil (India) Ltd was priced for profit growth of about 10.5% a year. Profit itself has compounded 14.6% a year over the past 10 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Grauer & Weil (India) Ltd story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Grauer & Weil (India) Ltd a stock worth studying right now?
This is not investment advice. The machine read: Grauer & Weil (India) Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!